Blog

Asia-Pacific is the fastest-growing region in the Global Autoinjectors Market Size, Share, Trends & Forecast 2020–2035 report at a 14.12% CAGR, rising from USD 2,811.46 Million in 2025 to USD 10,534.69 Million by 2035. Inside that number, India posts the fastest country growth rate in the entire study at 15.15%, and China becomes the region's largest market at USD 3,371.22 Million. The reason is not complicated: the patients are here, and device makers have started building where the patients are.

The demand pool nobody has treated yet

The IDF Diabetes Atlas (11th edition) counts 589 million adults living with diabetes today, projected to reach 852.5 million by 2050. China, India and Indonesia together account for 127.1 million people with undiagnosed diabetes, 50.5% of the world total, an untreated pool that converts into injectable-therapy demand as diagnosis improves. India alone had an estimated 89.8 million adults with diabetes, second only to China, with a projected 75% increase by 2050. The WHO Essential Medicines List now includes GLP-1 receptor agonists, and a new WHO prequalification track is opening LMIC procurement channels for GLP-1 and insulin products — the policy bridge between that demand and a device.

Capacity is following the demand

Ypsomed opened its Changzhou, China production site as part of a CHF 205.6 million property, plant and equipment programme spanning Switzerland, Schwerin and China, while building toward one billion devices of installed annual capacity. The report's regional and emerging-companies chapter profiles Jiangsu Delfu Medical Device, Jiangsu Jichun Medical Devices, Ypsomed China, Hualan Medical Device, Hindustan Syringes & Medical Devices (HMD), Lifelong Meditech, Poly Medicure and Hi-Tech Medics, alongside the Indian biosimilar and metabolic players Biocon Biologics, Wockhardt, Lupin, Sun Pharmaceutical, Zydus Lifesciences and Aurobindo Pharma, and China's Innovent Biologics.

Localisation also changes the cost equation the report's price chapter documents. Its Asia-Pacific, India and emerging-markets price-source section reads local reference prices against the region's own revenue lines, and its methodology notes address the availability discount that separates a listed price from an accessible one in tender-driven markets.

What is different about emerging-market demand

• Modality mix. Insulin and GLP-1 peptides lead rather than monoclonal antibodies, so the peptides-and-proteins modality and the up-to-1.0 mL container class carry more weight than in North America.
• Administrator type. Caregiver and family-member administration, quantified separately in the report, is a larger share of use than in Western home-care models.
• Biosimilar timing. Indian and Korean biosimilar makers are simultaneously suppliers to the US and Europe and the primary source of affordable biologics at home, so one autoinjector qualification serves both markets.
• Emergency access. School and public-access epinephrine stocking, quantified as distinct end-use settings, is at an earlier stage than in the 14 US states that currently mandate it.

The risks that travel with the opportunity

The report does not treat Asia-Pacific as a one-way bet. Counterfeit GLP-1 pens seized inside the legitimate US supply chain, recorded by the FDA, are a warning for every market with weaker serialisation. Oral GLP-1s, cheaper to produce and needing no refrigeration, are a stronger substitute where cold-chain and device cost bite hardest. And tariff regimes that pull manufacturing onshore in the US raise the cost of exporting from Asian plants. The report's base case still absorbs all three because the capacity being built — Neopak, YpsoMate and Stevanato-type lines — serves any subcutaneous biologic, not only GLP-1.

Where a manufacturer should look first

China for scale and the largest 2035 value; India for the fastest growth rate and the deepest undiagnosed pool; Japan for the most mature biologic prescribing base in the region. The report breaks each of the seven Asia-Pacific countries and sub-regions down by all 27 segment tables, so a device maker, primary-container supplier or CDMO can size the exact configuration — disposable versus reusable, 1 mL versus 2.25 mL, insulin versus antibody — it intends to build.

All market figures in this article are from the Global Data Route Analytics report Global Autoinjectors Market Size, Share, Trends & Forecast 2020–2035. External links open in a new tab and lead to the regulator, company or database sources cited in the report.